“So we think Livdelzi's trajectory is incredibly strong and we believe 2025 is going to be where it really comes through from a momentum standpoint.”

In context

“e're very much looking forward to that. And I think it has a lot to do with the experience, the heritage that we have in liver, the credibility that we bring with key stakeholders. So very pleased about that. The payer access we're seeing is also in line with our expectations. For rare disease, we're not seeing any major barriers to getting access for appropriate patients. To your question about what type of patients? Obviously, these are second-line patients in line with our indication. Generally speaking, these are naive to second line. And what I mean by that is obviously, they're inadequate responders to UDCA and moving into the second-line setting, but it's not -- we're not seeing much of a shift between second-line setting at this point in time, if that's what you were referring to. So we think Livdelzi's trajectory is incredibly strong and we believe 2025 is going to be where it really comes through from a momentum standpoint. So we're excited to see what the future holds. Operator: Our next question comes from Tyler Van Buren. Tyler, go ahead, your line is open. Tyler Van Buren: Thanks very much. Nice quarterly results. Johanna, I have another one for you. Just what led to the 16% year-over-year PrEP market growth and acceleration for 2024 that you highlighted? Specifically, can you elaborate on some of those factors and whether you think those might serve as lasting tailwinds for the upcoming lenacapavir launch? Johanna Mercier: Yeah. Thanks for the question, Tyler. Yeah, we were excited to see, right? We closed out the quarter at about 16% market growth. That reflects a couple of things. Number one, just the value and the noise around PURPOSE 1 and PURPOSE 2, I think is giving some momentum to this market in”